On Dec. 11, 2022, Novavax announced that the Switzerland�s Federal Office of Public Health and France�s Haute Autorit� de Sant� had expanded their recommendations for use of Nuvaxovid�(NVX-CoV2373) as a COVID-19 booster.

In Switzerland, the FOPH recommends use of Nuvaxovid as a booster in individuals aged 16 and older for the first booster after priming or after the third dose regardless of previous vaccine history. In France, the HAS now recommends Nuvaxovid as a homologous booster dose to enable people who have received a primary vaccination to receive a booster dose.